Method and kit for home controlled ovarian stimulation for in vitro fertilization

1. A method for home controlled ovarian stimulation in a female patient in preparation for in vitro fertilization (IVF) or egg freezing, the method comprising the steps of:

1) stimulating an increase in hormones that support growth and release of one or more mature eggs in the female patient;

2) suppressing luteinizing hormone (LH) release by the pituitary gland by either inserting vaginally in the female patient or administering orally to the female patient a GnRH antagonist in a therapeutically effective amount;

3) testing whether the female patient is ovulating using an ovulation predictor kit, wherein if (a) the testing shows the female patient is ovulating, then no further medications are administered to the female patient, or (b) the testing shows the female patient is not ovulating, then the method proceeds to step 4;

4) administering a leuprorelin or nafarelin nasal spray to the female patient, in a therapeutically effective amount one or more times per day for a first day, wherein on the first day of administering the leuprorelin or nafarelin nasal spray to the female patient,

a. testing whether the female patient is ovulating using an ovulation predictor kit each time before administering the leuprorelin or nafarelin nasal spray to the female patient, wherein if (a) the testing shows the female patient is ovulating, then no further medications are administered to the female patient, or (b) the testing shows the female patient is not ovulating, then the method proceeds to step 5; and

5) administering a leuprorelin or nafarelin nasal spray to the female patient in a therapeutically effective amount one or more times per day for a second day, wherein on the second day of administering the leuprorelin or nafarelin nasal spray to the female patient,

a. testing whether the female patient is ovulating using an ovulation predictor kit each time before administering the leuprorelin or nafarelin nasal spray to the female patient, wherein if the testing shows the female patient is ovulating, then the controlled ovarian stimulation is successful.

2. The method of claim 1 , wherein the GnRH antagonist is elagolix, linzagolix or relugolix.

3. The method of claim 1 , wherein the GnRH antagonist is elagolix.

4. The method of claim 1 , wherein the therapeutically effective amount of the GnRH antagonist is 25 to 200 mg per day.

5. The method of claim 1 , wherein the therapeutically effective amount of the GnRH antagonist is 25 mg per day.

6. The method of claim 1 , wherein the GnRH antagonist is either inserted vaginally in the female patient or administered orally to the female patient on day 9 of the female patient's menstrual cycle.

7. The method of claim 1 , wherein the GnRH antagonist is either inserted vaginally in or administered orally to the female patient on day 9 and on day 11 of the female patient's menstrual cycle.

8. The method of claim 1 , wherein the therapeutically effective amount of leuprorelin or nafarelin nasal spray is three sprays per nostril, wherein each spray contains 0.05 mL of leuprorelin or nafarelin.

9. The method of claim 1 , wherein the step of administering the leuprorelin or nafarelin nasal spray according to step 4 or step 5 comprises:

a. administering 3 sprays of the leuprorelin or nafarelin nasal spray in each nostril of the female patient, waiting 10 minutes and repeating administering 3 sprays of the leuprorelin or nafarelin nasal spray in each nostril of the female patient;

b. waiting approximately 12 hours; and

c. administering 3 sprays of the leuprorelin or nafarelin nasal spray in each nostril of the female patient, waiting 10 minutes and repeating administering 3 sprays of the leuprorelin or nafarelin nasal spray in each nostril of the female patient.